Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial.
Francesco PerroneMaria Carmela PiccirilloPaolo Antonio AsciertoCarlo SalvaraniRoberto ParrellaAnna Maria MarataPatrizia PopoliLaurenzia FerrarisMassimiliano M Marrocco-TrischittaDiego RipamontiFrancesca BindaPaolo BonfantiNicola SquillaceFrancesco CastelliMaria Lorenza MuiesanMiriam LichtnerCarlo CalzettiNicola Duccio SalernoLuigi AtripaldiMarco CascellaMassimo CostantiniGiovanni DolciNicola Cosimo FacciolongoFiorentino FraganzaMarco MassariVincenzo MontesarchioCristina MussiniEmanuele Alberto NegriGerardo BottiClaudia CardonePiera GargiuloAdriano GravinaClorinda SchettinoLaura ArenarePaolo ChiodiniCiro Gallonull nullPublished in: Journal of translational medicine (2020)
Tocilizumab reduced lethality rate at 30 days compared with null hypothesis, without significant toxicity. Possibly, this effect could be limited to patients not requiring mechanical respiratory support at baseline. Registration EudraCT (2020-001110-38); clinicaltrials.gov (NCT04317092).